MUDr. Jiří Tomášek, Ph.D.
Assistant professor, Comprehensive Cancer Care Department
Total number of publications: 192
2013
-
Koincidence karcinomu ledvinya Gaucherovy choroby
Onkologie, year: 2013, volume: 7(2)
-
Maligní melanom léčený intenzivní chemoterapií, podobnost histologického obrazu maligního melanomu a nádorů měkkých tkání, kazuistika pacientky
Klinická onkologie, year: 2013, volume: 26, edition: 1
-
Nový prediktivní molekulární marker RAS umožňuje přesnější indikaci inhibitorů EGFR v léčbě metastatického kolorektálního karcinomu
Farmakoterapie, year: 2013, volume: 2013, edition: 6
-
Onkogeny RAS – prediktivní molekulární marker u kolorektálního karcinomu
Klinická onkologie, year: 2013
-
Open-label, phase IIIb, multicenter, expanded access study of everolimus in patients with advanced neuroendocrine tumors (NET).
Year: 2013, type: Appeared in Conference without Proceedings
-
Pacient s metastatickým kolorektálním karcinomem léčený multimodálním přístupem
Acta medicinae, year: 2013, volume: 2
-
Phase Ib safety trial of CVX-060, an intravenous humanized monoclonal CovX body inhibiting angiopoietin 2 (Ang-2), with axitinib in patients with previously treated metastatic renal cell cancer (RCC). Abstract No: 2533
Year: 2013, type: Appeared in Conference without Proceedings
-
REGARD PHASE 3, RANDOMIZED TRIAL OF RAMUCIRUMAB IN PATIENTS WITH METASTATIC GASTRIC OR GEJ ADENOCARCINOMA FOLLOWING PROGRESSION ON FIRST-LINE CHEMOTHERAPY
Year: 2013, type: Appeared in Conference without Proceedings
-
REGARD: A phase III, randomized, double-blind trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy
Year: 2013, type: Appeared in Conference without Proceedings
-
REGARD: A phase III, randomized, double-blind trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy
Year: 2013